The Prognosis of Leptin rs2167270 G > A (G19A) Polymorphism in the Risk of Cancer: A Meta-Analysis

Aiqiao Zhang1,2†, Shangren Wang3†, Fujun Zhang1,2, Wei Li1,2, Qian Li1,2 and Xiaoqiang Liu3*

1 Department of Neonatology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, 2 Department of Neonatology, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China, 3 Department of Urology, Tianjin Medical University General Hospital, Tianjin, China

Background: Although the effect of the LEP G19A (rs2167270) polymorphism on cancers is assumed, the results of its influence have been contradictory. A meta-analysis was conducted to precisely verify the relationships between LEP G19A and the development of digestion-related cancers.

Methods: Investigators systematically searched the literature in PubMed, Embase, and Web of Science and used STATA software 14.0 for the meta-analysis. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the associations. Subgroup analyses stratified by ethnicity, cancer type, and cancer system were further conducted to assess the relationship between the LEP G19A polymorphism and digestion-related cancers.

Results: In the overall population, we found a significant relationship with overall cancer (allele comparison: OR = 0.921, p = 0.000; dominant comparison: OR = 0.923, p = 0.004; recessive comparison: OR = 0.842, p = 0.000; homozygote model: OR = 0.0843, p = 0.001). In a subgroup analysis conducted by ethnicity, we obtained significant results in Asians (Asian allele comparison: OR = 0.885, p = 0.000; dominant comparison: OR = 0.862, p = 0.000; homozygote model: OR = 0.824, p = 0.039; and heterozygote comparison: OR = 0.868, p = 0.000) but not in Caucasians. In a subgroup analysis conducted by cancer type and cancer system, we obtained significant results that the LEP G19A polymorphism may decrease the risk of colorectal cancer, esophageal cancer, digestive system cancer, and urinary system cancer.

Conclusions: This meta-analysis revealed that the LEP G19A polymorphism may decrease the risk of cancer.

Keywords: leptin (LEP), cancer, polymorphism, A19G, rs2167270

INTRODUCTION

It is well known that cancer is one of major causes of death with over 6.1 million projected to die each year, and morbidity rates have increased gradually over the past decade (1, 2), so it has been a public health burden worldwide. The reason for cancer is complicated and the etiology and mechanism of carcinogenesis are not clearly elucidated to date. It was widely accepted that the interplay between...
environmental factors, genetics, and lifestyle plays an important role in the carcinogenesis according to epidemiology. There is mounting evidence indicating that many metabolic diseases such as obesity and diabetes may significantly increase the risk of cancer (3–5). The polymorphism of obesity and diabetes gene may be associated with genetic susceptibility of cancer.

Leptin (LEP), a 16-kDa hormone of energy expenditure, is a balancing mediator of homeostasis by regulating acquisition and consumption of energy, which was a basic pathophysiological process in normal cells and cancer cells. Many epidemiological studies have revealed the link between LEP and the development of many kinds of cancers (6–8). Among the pathophysiological mechanisms of cancer, LEP seems relevant to the proliferation of cancer stem cells (9). Some studies also revealed that LEP through its signal pathways regulating energy intake and expenditure [MAPK, PI3K, mTOR, and JAK/STAT (10, 11)] produced an effect in angiogenesis processes that were critical in the genesis and development of cancer (12). Pathophysiological mechanisms of cancer such as inflammation, invasion, and metastasis are also favored by LEP (13–15). So, LEP may be involved in various pathological processes of carcinogenesis.

Single-nucleotide polymorphism can change the functions of genes and the expression of protein. LEP G19A polymorphism, positioning at the 5′-untranslated region of gene, may impact mRNA translation and change the serum level of LEP. With the development of molecular epidemiology, various studies have demonstrated that LEP G19A polymorphism is related to cancer risk (16–19). However, results between G19A polymorphism with cancers have been inconsistent or inconclusive. Therefore, we performed a metaanalysis to verify the correlation between the G19A mutation of the LEP gene and susceptibility to cancers.

In this study, we conducted a meta-analysis to verify whether the G19A polymorphism of the LEP gene affects the risk of cancer.

METHODS

Literature Search
A comprehensive literature search of PubMed, Embase, and Web of Science was performed to search all potential studies that involved the relevance between the G19A polymorphism and cancers prior to June 2021. Our study contained the following terms: (“leptin” OR “LEP” OR “G19A” OR “rs2167270”) AND (“polymorphism” OR “variant” OR “mutation”) AND (“malignancy” OR “cancer” OR “carcinoma” OR “neoplasm”).

Inclusion and Exclusion Criteria
The inclusion criteria were as follows: (1) investigate the association between the LEP G19A (rs2167270) mutation and cancers; (2) meet cohort design or case–control design; (3) abundant data should behave to estimate an odds ratio (OR) and 95% confidence interval; (4) results were reported in English; and (5) include human subjects. We adopted the following exclusion criteria: (1) duplicated studies; (2) studies in which subjects were not human; and (3) studies in which we could not obtain sufficient raw data.

Data Extraction
Investigators extracted genotype data independently, and every data point reached a consensus. The extracted data contained the (1) name of the first author; (2) year of publication; (3) ethnicity of cases and controls; (4) cancer type of studies; and (5) frequency of LEP G19A in genes.

Statistical Analysis
We computed ORs and their 95% CIs to estimate the association between the LEP G19A (rs2167270) mutation and cancers. The pooled ORs and their 95% CIs were computed for genes using the following five models: dominant model (AA + AG vs. GG), recessive model (AA vs. GG + AG), allele model (A vs. G), homozygous model (AA vs. GG), and heterozygote model (AG vs. GG).

The Q test was used to estimate heterogeneity between different studies, and $p < 0.05$ was considered significant for heterogeneity. In addition, inconsistency was quantified by the $I^2$ statistic. Twenty-five percent and 50% of the $I^2$ values indicated low and high levels of heterogeneity, respectively. An $I^2 < 50\%$ suggested that no heterogeneity existed. When heterogeneity existed, the fixed effects model (FEM) was utilized; otherwise, the random-effects model (REM) was utilized for calculation.

To evaluate the specific effects of ethnicity, cancer type, and cancer system, investigators performed subgroup analyses by ethnicity, cancer type, and cancer system. Sensitivity analyses were performed to evaluate the stability of the results. A funnel plot of Egger’s or Begg’s test was conducted to reveal possible publication bias. We used the Newcastle-Ottawa Scale to assess the including literature quality. All meta-analyses were performed using STATA software (Version 12.0, College Station, TX).

RESULTS

Study Characteristics
Depending on the search strategy, 633 articles were retrieved (Figure 1). Among them, 103 articles were eligible after excluding repeated publications. By reviewing the titles and study abstracts, 58 articles were excluded. Of the remaining 45 studies, 26 articles were excluded, including 11 studies that were not focused on the LEP G19A genetic mutation. Five studies were meta-analyses. Eight studies were on other disorders that were not cancer. Two articles did not provide raw data. Finally, 19 studies conformed to our meta-analyses, and Tables 1 and 2 summarize the extracted data (16–34).

Effect of the LEP G19A Polymorphism on Cancers
We investigated the effect of the LEP G19A mutation on cancer susceptibility in five genetic models. In all models, if the heterogeneity was less than 50%, the authors applied fixed models, whereas if the heterogeneity was greater than 50%, random models were used.

In the overall population, we found a significant relationship with cancer in four models (allele comparison: OR = 0.921, p =
In a subgroup analysis conducted by cancer type, we obtained significant results that the LEP G19A polymorphism decreased the risk of colorectal cancer in one model (recessive model: OR = 0.816, \( p = 0.010 \)); decreased the risk of esophageal cancer in two models (allele model: OR = 0.888, \( p = 0.014 \); dominant comparison: OR = 0.874, \( p = 0.022 \)); and decreased the risk of other types of cancer in three models (allele comparison: OR = 0.866, \( p = 0.010 \); dominant comparison: OR = 0.842, \( p = 0.010 \); heterozygote comparison: OR = 0.849, \( p = 0.018 \)) (Table 3 and Figure 2).

In a subgroup analysis conducted by cancer system, we obtained significant results that the LEP G19A polymorphism decreased the risk of digestive system cancer in three models (allele comparison: OR = 0.937, \( p = 0.016 \); recessive comparison: OR = 0.838, \( p = 0.005 \); homozygote comparison: OR = 0.863, \( p = 0.028 \)); we also obtained significant results that the LEP G19A polymorphism decreased the risk of urinary system cancer in three models (allele comparison: OR = 0.881, \( p = 0.022 \); dominant comparison: OR = 0.842, \( p = 0.019 \); heterozygote comparison: OR = 0.855, \( p = 0.043 \)) (Table 3 and Figure 2).

**Sensitivity Analysis and Publication Bias**

We used Begg’s and Egger’s tests to evaluate publication bias in all models. All results of Begg’s and Egger’s tests were >0.05 in all models and funnel plots, revealing that publication bias may not exist among our studies (Table 2, Figures 3 and 4). We conducted a sensitivity analysis, and pooled ORs and the corresponding 95% CIs were computed. The results did not show a significant change even though one study was deleted each time, which suggested that the results were statistically stable (Figure 5).

**DISCUSSION**

It has been confirmed that the occurrence of cancer is a complex, multistep, and multifactorial event that contains various genetic,
### TABLE 2 | Distribution of LEP G19A polymorphism genotype and allele.

| Author               | Year | Genotype distribution | HWE |
|----------------------|------|-----------------------|-----|
|                      |      | Case                  |     |
|                      |      | AA | AG | GG | A | G |
| Skibola et al. (16)  | 2004 | 36 | 169 | 168 | 241 | 506 |
| Willett et al. (17)  | 2005 | 79 | 276 | 235 | 434 | 746 |
| Slattery et al. (18) | 2008 | 190 | 766 | 611 | 1,116 | 1,988 |
| Doecke et al. (20)   | 2008 | 34 | 130 | 94 | 198 | 318 |
| Tsilidis et al. (19) | 2009 | 39 | 122 | 92 | 200 | 306 |
| Wang et al. (21)     | 2009 | 113 | 404 | 428 | 630 | 1,260 |
| Moore et al. (22)    | 2010 | 7 | 44 | 17 | 58 | 78 |
| Partida-Perez et al. (23) | 2010 | 12 | 110 | 245 | 148 | 148 |
| Skibola et al. (16)  | 2004 | 36 | 169 | 168 | 241 | 506 |
| Willett et al. (17)  | 2005 | 79 | 276 | 235 | 434 | 746 |
| Slattery et al. (18) | 2008 | 190 | 766 | 611 | 1,116 | 1,988 |
| Doecke et al. (20)   | 2008 | 34 | 130 | 94 | 198 | 318 |
| Tsilidis et al. (19) | 2009 | 39 | 122 | 92 | 200 | 306 |
| Wang et al. (21)     | 2009 | 113 | 404 | 428 | 630 | 1,260 |
| Moore et al. (22)    | 2010 | 7 | 44 | 17 | 58 | 78 |
| Partida-Perez et al. (23) | 2010 | 12 | 110 | 245 | 148 | 148 |

### TABLE 3 | The association between LEP G19A and cancer susceptibility.

| G19A | No | A vs. G | p* | OR (95% CI) | p* | OR (95% CI) | p* | OR (95% CI) | p* | OR (95% CI) | p* | OR (95% CI) |
|------|----|---------|----|-------------|----|-------------|----|-------------|----|-------------|----|-------------|
|      |    | A+AG vs. GG |     |             |    |             |    |             |    |             |    |             |
|      |    | AA+AG vs. GG |     |             |    |             |    |             |    |             |    |             |
|      |    | AA vs. AG+GG |     |             |    |             |    |             |    |             |    |             |
|      |    | AA vs. GG |     |             |    |             |    |             |    |             |    |             |
|      |    | AG vs. GG |     |             |    |             |    |             |    |             |    |             |

The meaning of bold values is statistically significant (P<0.05).

*P value of Q test for heterogeneity test; **P value of Begg rank for testing publication bias; ***P value of Egger rank for testing publication bias.

HWE, Hardy–Weinberg equilibrium.
environmental, and lifestyle factors, such as smoking, drinking, obesity, and genetic factor. Multiple studies have revealed that metabolic-related factors are associated with the risk of cancer (35–37). The LEP, metabolic-related factors regulating balancing by regulating acquisition and energy consumption, was confirmed relevant to cancer (38–40). The LEP G19A polymorphism may alter the transcription of mRNA and the level of LEP was confirmed to be associated with any kind of cancer (21, 22, 24–26). However, the conclusions of those studies were inconsistent. Two meta-analyses were researched by Liu et al. (41), including 10 studies, and Yang et al. (29), including 13 studies, generating conflicting results in subgroup analysis and
lacking subgroup analysis of the cancer system. Meanwhile, an expanding body of literature on the relationship between LEP G19A polymorphism and cancer risk has been published. Therefore, we conducted this meta-analysis to address this relevance between the LEP G19A polymorphism and cancer risk.

Our current meta-analysis contained 19 studies of cancers containing 9,878 patients, and 14,251 controls were pooled, which contained more participants and cancer types than the previous meta-analysis. Overall, we found a significant correlation between the LEP G19A mutation and susceptibility to cancers under four models (allele model, dominant model, recessive model, and homozygote model), which means that this mutation may decrease the risk of overall cancer. This result was confirmed in a meta-analysis conducted by Liu et al. (41) and Yang et al. (29). Studies (42, 43) confirmed that the LEP G19A mutation might reduce mRNA translation with a lower serum level of LEP, which may attenuate the cancer risk as a protective factor.

Obesity was defined as an imbalance between caloric consumption and energy expenditure. Meanwhile, the LEP is a metabolic-related factor regulating balancing by regulating acquisition and consumption of energy. So it seems that obesity has a positive correlation with LEP polymorphism. However, some studies showed that there was no association between LEP polymorphism and obesity (44, 45). Mizuta et al. (46) study showed that LEP G19A was not associated with obesity. The study by Nesrine et al. (47) even showed that different polymorphisms of the LEP gene have distinct correlations with obesity. Our study showed that LEP G19A polymorphism decreases cancer risk, but the exact mechanism is unknown and mounting evidence indicates that obesity may greatly increase the risk of cancer (3–5). This provides us with a
hint that LEP G19A polymorphism may not lead to cancer by gaining weight. Further studies are needed to elucidate the mechanism of action of LEP G19A polymorphism and cancer.

When stratified by ethnicity, we found a significant correlation between this mutation and Asians and no significant in Caucasians, which means that this mutation may decrease the risk of Asian people not Caucasians. This difference might be caused by a discrepancy in the interplay between genes and the environment. Moreover, the frequency of the A allele in Caucasians (68%) and Asians (44%) might be the reason for contributing to the discrepancy in the non-significant results in Caucasians. When stratified by cancer type and cancer system, it was first to describe the association between LEP G19A mutation and the cancer system. We found a significant correlation between this mutation and colorectal cancer, esophageal cancer, digestive system cancer, and urinary system cancer, which means that this mutation may decrease the risk of colorectal cancer, esophageal cancer, digestive system cancer, and urinary system cancer, but we found no correlation between this mutation and the other cancer system; the reason for this difference in risk with different tumors is as yet unknown, possibly due to LEP and its receptors playing various roles in the mediation of physiological reactions and carcinogenesis in different pathological types of cancer.

Heterogeneity may exist in our meta-analysis of cancer in the overall analysis. Stratified analyses indicated that heterogeneity was significant in some subgroups (e.g., Asians, esophageal cancer, and urinary system cancer). These factors may cause heterogeneity in our study. We checked the stability of our pooled results by sensitivity analyses. The trend of relevance was not significantly changed in the sensitivity analyses, which meant that the pooled results in our meta-analysis were statistically stable. We used Begg’s and Egger’s tests to evaluate publication bias. Begg’s and Egger’s tests’ p-values > 0.05 in all models, so that publication bias may exist in this meta-analysis. The following limitations should be mentioned: (1) The number of studies focused on the relationship between LEP G19A and cancer was relatively small, so little information about stratified analyses of ethnicity, cancer type, and cancer system was available; therefore, further studies are required to determine the actual relationship in all populations. (2) Our study had no access to other potential factors influencing the results, such as other lifestyles, environments, and ages.

CONCLUSION

In conclusion, this meta-analysis suggests that the LEP G19A mutation may decrease the risk of overall cancer, colorectal cancer, esophageal cancer, digestive system cancer, and urinary system cancer. In the future, more comprehensive objects containing genetic environmental interaction are warranted to discover the correlation between LEP G19A mutation and the risk of cancer.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

AZ, SW, FZ, WL, QL, and XL conceived the study. FZ, WL, and QL contributed to data acquisition, data interpretation, and statistical analysis. AZ, SW, and XL contributed to the study design, statistical analysis, writing, and revising of the manuscript critically. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Natural Science Funds of China (82171594) and Zhao Yi-Cheng Medical Science Foundation (ZYYFY2018031).

ACKNOWLEDGMENTS

We thank all authors whose studies were included in our meta-analysis.

REFERENCES

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin (2021) 71:7–33. doi: 10.3332/caac.21654
2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin (2020) 70:7–30. doi: 10.3332/caac.21590
3. Kolb R, Sutterwala FS, Zhang W. Obesity and Cancer: Inflammation Bridges the Two. Curr Opin Pharmacol (2016) 29:77–89. doi: 10.1016/j.coph.2016.07.005
4. Dalamaga M, Christodoulatos GS, Mantzoros CS. The Role of Extracellular and Intracellular Nicotinamide Phosphoribosyl-Transferase In Cancer: Diagnostic and Therapeutic Perspectives and Challenges. Metabolism (2018) 82:72–87. doi: 10.1016/j.metabol.2018.01.001
5. Garg SK, Maurer H, Reed K, Selagamsetty R. Diabetes and Cancer: Two Diseases With Obesity as a Common Risk Factor. Diabetes Obes Metab (2014) 16:97–110. doi: 10.1111/dom.12124
6. Bieniewicz J, Romanowicz H, Wlaczynski M, Jabłoński G, Stępień A, Obłębkowska A, et al. Association of Single Nucleotide Polymorphism LEP-R C.668A>G (P.Gln223Arg, Rs1137101) of Leptin Receptor Gene With Endometrial Cancer. BMC Cancer (2021) 21:925. doi: 10.1186/s12885-021-08620-y
7. Holysz H, Paszal-Jaworska A, Romaniuk-Drapala A, Grodecka-Gazdecka S, Rubisz B. LEP (-2548g>A LEP) and LEPR (223gln>Arg, 109lys>Arg) Polymorphisms as Breast Cancer Risk Factors in the Polish Female Population. Mol Biol Rep (2021) 48:3237–44. doi: 10.1007/s13059-021-06328-7
8. Tayel SI, Alhanaﬁ AM, Ahmed SM, Eltorgaman AA, Elsayed EI. Biochemical Study on Modifying Role of Variants of Leptin Gene and its Receptor on Serum Leptin Levels in Breast Cancer. Mol Biol Rep (2020) 47:3807–20. doi: 10.1007/s11033-020-05436-0
9. Delort L, Bougaret L, Cholet J, Vermerie M, Billard H, Decombat C, et al. Hormonal Therapy Resistance and Breast Cancer: Involvement of Adipocytes and Leptin. Nutrients (2019) 11(12):2839–55. doi: 10.3390/nu11122839
10. Ghasemi A, Saeidi J, Azimi-Nejad M, Hashemly SI. Leptin-Induced Signaling Pathways in Cancer Cell Migration and Invasion. Cell Oncol (Dordr) (2019) 42:243–60. doi: 10.1007/s13402-019-00428-0
11. Ola–Flores M, Juárez–Cruz JC, Mendoza–Catalán MA, Padilla–Benavides T, Navarro–Tito N. Signaling Pathways Induced by Leptin During Epithelial–Mesenchymal Transition in Breast Cancer. *Int J Mol Sci* (2018) 19(11):3493–513. doi: 10.3390/ijms19113493

12. Llanos A, Yao S, Singh A, Areu JB, Khabianian H, Lin Y, et al. Gene Expression of Adipokines and Adipokine Receptors in the Tumor Microenvironment: Associations of Lower Expression With More Aggressive Breast Cancer Features. *Breast Cancer Res Treat* (2021) 185:785–98. doi: 10.1007/s10549-020-05972-0

13. Zhang S, Jiang J, Chen Z, Wang Y, Tang W, Liu C, et al. Investigation of LEP and LEPR Polymorphisms With the Risk of Hepatocellular Cancer: A Case-Control Study Involving 2,306 Subjects. *Am J Transl Res* (2020) 12:5613–28. doi: 10.1200/ajco.2020.38.15_suppl.e16100

14. Huang BZ, Tsilidis KK, Smith MW, Hoffman-Bolton J, Visvanathan K, Platz EA, et al. Polymorphisms in Genes Related to Inflammation and Obesity and Colorectal Adenoma Risk. *Mol Carcinog* (2018) 57:1278–88. doi: 10.1002/mc.22842

15. Ray A, Cleary MP. The Potential Role of Leptin in Tumor Invasion and Metastasis. *Cytokine Growth Factor Rev* (2017) 38:80–97. doi: 10.1016/j.cytogfr.2017.11.002

16. Skibola CF, Adamsen P, Skibola DR, et al. Body Mass Index, Leptin and Leptin Receptor Polymorphisms, and non-Hodgkin Lymphoma. *Cancer Epidemiol Biomarkers Prev* (2004) 13:779–86.

17. Skibola CF, Holly EA, Tenneson P, Skibola DR, et al. Non-Hodgkin’s Lymphoma, Obesity and Energy Homeostasis Polymorphisms. *Br J Cancer* (2005) 93:811–6. doi: 10.1038/sj.bjc.6602762

18. Winkler TR, Coll SE, Adamsen P, Skibola DR, et al. Obesity and Energy Homeostasis Polymorphisms. *Br J Cancer* (2005) 93:811–6. doi: 10.1038/sj.bjc.6602762

19. Slattery ML, Wolf RK, Herrick J, Caan BJ, Potter JD. Leptin and Leptin Receptor Genotypes and Colon Cancer: Gene–Gene and Gene–Lifestyle Interactions. *Int J Cancer* (2008) 122:1611–7. doi: 10.1002/ijc.23135

20. Tailidis K, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp SL, et al. Association of Common Polymorphisms in IL10, and in Other Genes Related to Inflammatory Response and Obesity With Colorectal Cancer. *Cancer Causes Control* (2009) 20:1739–51. doi: 10.1007/s10552-009-9427-7

21. Dooeke JD, Zhao ZZ, Stark MS, Green AC, Hayward NK, Montgomery GW, et al. Single Nucleotide Polymorphisms in Obesity-Related Genes and the Risk of Esophageal Cancers. *Cancer Epidemiol Biomarkers Prev* (2008) 17:1007–12. doi: 10.1158/1055-9965.EPI-08-0023

22. Slattery ML, Wolf RK, Herrick J, Caan BJ, Potter JD. Leptin and Leptin Receptor Genotypes and Colon Cancer: Gene–Gene and Gene–Lifestyle Interactions. *Int J Cancer* (2008) 122:1611–7. doi: 10.1002/ijc.23135

23. Tailidis K, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp SL, et al. Association of Common Polymorphisms in IL10, and in Other Genes Related to Inflammatory Response and Obesity With Colorectal Cancer. *Cancer Causes Control* (2009) 20:1739–51. doi: 10.1007/s10552-009-9427-7

24. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, et al. Association of IL10 and Other Immune Response- and Obesity-Related Genes With Prostate Cancer in CLUE II. *Prostate* (2009) 69:874–85. doi: 10.1002/pros.20933

25. Moore SC, Leitzmann MF, Albanes D, Weinstein SJ, Snyder K, Virtamo J, et al. Single Nucleotide Polymorphisms in Obesity-Related Genes are Associated With Age at Menarche and Obesity in Menopause in Breast Cancer Patients and Healthy Women. *Hum Reprod* (2012) 27:2193–200. doi: 10.1093/humrep/des147

26. Zhang S, Wang MY, He J, Wang JC, Yang YJ, Jin L, et al. Tumor Necrosis Factor-α Induced Protein 8 Polymorphism and Risk of non-Hodgkin’s Lymphoma in a Chinese Population: A Case-Control Study. *PloS One* (2012) 7:e37846. doi: 10.1371/journal.pone.0037846

27. Qiou H, Lin X, Tang W, Liu C, Chen Y, Ding H, et al. Investigation of TCFL2L1, LEP and LEPR Polymorphisms With Esophageal Squamous Cell Carcinomas. *Oncotarget* (2017) 8:109170–19. doi: 10.18632/oncotarget.22619

28. Zhang S, Jiang J, Chen Z, Wang Y, Tang W, Liu C, et al. Investigation of LEP and LEPR Polymorphisms With the Risk of Hepatocellular Carcinoma: A Case-Control Study in Eastern Chinese Han Population. *Onco Targets Ther* (2018) 11:2083–9. doi: 10.2147/OTT.S153931

29. Zhang S, Jiang J, Chen Z, Wang Y, Tang W, Liu C, et al. Investigation of LEP and LEPR Polymorphisms With the Risk of Hepatocellular Carcinoma: A Case-Control Study in Eastern Chinese Han Population. *Onco Targets Ther* (2018) 11:2083–9. doi: 10.2147/OTT.S153931

30. Zhang X, Jiang J, Chen Z, Wang Y, Tang W, Liu C, et al. Investigation of LEP and LEPR Polymorphisms With the Risk of Hepatocellular Carcinoma: A Case-Control Study in Eastern Chinese Han Population. *Onco Targets Ther* (2018) 11:2083–9. doi: 10.2147/OTT.S153931

31. Zhang S, Jiang J, Chen Z, Wang Y, Tang W, Liu C, et al. Investigation of LEP and LEPR Polymorphisms With the Risk of Hepatocellular Carcinoma: A Case-Control Study in Eastern Chinese Han Population. *Onco Targets Ther* (2018) 11:2083–9. doi: 10.2147/OTT.S153931

32. Zhang X, Jiang J, Chen Z, Wang Y, Tang W, Liu C, et al. Investigation of LEP and LEPR Polymorphisms With the Risk of Hepatocellular Carcinoma: A Case-Control Study in Eastern Chinese Han Population. *Onco Targets Ther* (2018) 11:2083–9. doi: 10.2147/OTT.S153931

33. Zhang X, Jiang J, Chen Z, Wang Y, Tang W, Liu C, et al. Investigation of LEP and LEPR Polymorphisms With the Risk of Hepatocellular Carcinoma: A Case-Control Study in Eastern Chinese Han Population. *Onco Targets Ther* (2018) 11:2083–9. doi: 10.2147/OTT.S153931

34. Zhang X, Jiang J, Chen Z, Wang Y, Tang W, Liu C, et al. Investigation of LEP and LEPR Polymorphisms With the Risk of Hepatocellular Carcinoma: A Case-Control Study in Eastern Chinese Han Population. *Onco Targets Ther* (2018) 11:2083–9. doi: 10.2147/OTT.S153931

35. Zhang X, Jiang J, Chen Z, Wang Y, Tang W, Liu C, et al. Investigation of LEP and LEPR Polymorphisms With the Risk of Hepatocellular Carcinoma: A Case-Control Study in Eastern Chinese Han Population. *Onco Targets Ther* (2018) 11:2083–9. doi: 10.2147/OTT.S153931

36. Zhang X, Jiang J, Chen Z, Wang Y, Tang W, Liu C, et al. Investigation of LEP and LEPR Polymorphisms With the Risk of Hepatocellular Carcinoma: A Case-Control Study in Eastern Chinese Han Population. *Onco Targets Ther* (2018) 11:2083–9. doi: 10.2147/OTT.S153931

37. Zhang X, Jiang J, Chen Z, Wang Y, Tang W, Liu C, et al. Investigation of LEP and LEPR Polymorphisms With the Risk of Hepatocellular Carcinoma: A Case-Control Study in Eastern Chinese Han Population. *Onco Targets Ther* (2018) 11:2083–9. doi: 10.2147/OTT.S153931

38. Zhang X, Jiang J, Chen Z, Wang Y, Tang W, Liu C, et al. Investigation of LEP and LEPR Polymorphisms With the Risk of Hepatocellular Carcinoma: A Case-Control Study in Eastern Chinese Han Population. *Onco Targets Ther* (2018) 11:2083–9. doi: 10.2147/OTT.S153931

39. Zhang X, Jiang J, Chen Z, Wang Y, Tang W, Liu C, et al. Investigation of LEP and LEPR Polymorphisms With the Risk of Hepatocellular Carcinoma: A Case-Control Study in Eastern Chinese Han Population. *Onco Targets Ther* (2018) 11:2083–9. doi: 10.2147/OTT.S153931
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhang, Wang, Zhang, Li, Li and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.